Researchers at Northwestern Medicine have identified immune system markers that may help predict which patients respond to BCG bladder cancer therapy and which do not, according to findings published in the Journal of Clinical Investigation. The discovery could enable clinicians to tailor treatment strategies, sparing non-responders from ineffective therapy and its side effects while directing them toward alternative options.
Bladder cancer is the sixth most common cancer in the United States, with BCG (bacillus Calmette-Guérin) immunotherapy being a standard treatment for high-risk non-muscle invasive bladder cancer. However, about 30-40% of patients do not respond to BCG, and currently there are no reliable biomarkers to predict response. The Northwestern team analyzed immune cell populations in tumor samples from patients before and after BCG treatment, identifying specific patterns associated with favorable outcomes.
The study found that patients who responded to BCG had higher levels of certain immune cells, including CD8+ T cells and natural killer cells, as well as distinct gene expression profiles related to immune activation. Non-responders, in contrast, showed elevated markers of immune suppression. These biomarkers could be used to stratify patients prior to treatment, potentially guiding clinical decisions.
While the findings are promising, the researchers caution that larger studies are needed to validate the biomarkers before they can be implemented in clinical practice. The work builds on a growing understanding of the immune system's role in cancer therapy, with implications beyond bladder cancer. As immunotherapy continues to evolve, companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also working to refine immunotherapeutic approaches for various cancers.
The identification of predictive biomarkers represents a step toward personalized medicine in bladder cancer, potentially improving patient outcomes and reducing healthcare costs by avoiding ineffective treatments. Further research will focus on translating these findings into clinical tests that can be used in routine care.
